Background/aim: To evaluate the opioid prescription patterns across ophthalmic subspecialties at a large academic eye centre.
Methods: A single site, retrospective cross-sectional study. Electronic medical records from the year 2018 were screened. Ophthalmology patients ≥18 years of age were included. The main outcome measures were patient demographics, outpatient opioid prescriptions, ophthalmic procedure and prescriber details, including department and training level.
Results: 1654 opioid prescriptions were written, accounting for 2.2% of all ophthalmic procedures in a calendar year. Of the patients who received prescriptions, 51.4% were female (n=851) with a mean age of 52.3±18.5 (range 18-95 years). In general, the morphine equivalent dose was low, with an average of 12.4±6.75 pills dispensed (range 1-60) with 0.0±0.01 refills (range 0-3). Cornea specialists were the highest opioid prescribers (22.7% of all providers who wrote a prescription), followed by oculoplastics (22.2%) and retina (18.4%). The most common procedure for which an opioid was prescribed was cornea crosslinking (14.3% of all opioid prescriptions).
Conclusions: While opioid prescriptions are generally low for ophthalmic procedures across departments, cornea specialists accounted for nearly a third of opioid prescriptions. Over half of corneal crosslinking patients received opioid prescriptions; there remains an unmet need for opioid-sparing therapy for these patients and others with severe eye pain.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877224 | PMC |
http://dx.doi.org/10.1136/bmjophth-2024-002012 | DOI Listing |
J Pain Res
March 2025
Division of Pharmaceutical Evaluation and Policy, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Importance: This study addresses the critical need for an evidence-based instrument to assess the likelihood of NSAID-induced cardiovascular events, that provides clinicians with valuable decision support to improve safety in their use for pain management, especially in patients vulnerable to cardiovascular events.
Objective: To develop a practical risk scoring tool, NSAID Induced Cardiovascular Events (NAÏVE), for estimating the risk of serious cardiovascular events associated with NSAID use.
Design: Retrospective nested case-control study.
Rheumatology (Oxford)
March 2025
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Objectives: Recent studies have raised concerns regarding usage of opioids, a class of drugs widely used for managing chronic pain in musculoskeletal disorders; however, its potential risks remain incompletely understood. This study aimed to evaluate the association between oral opioid use and mortality in a nationwide inflammatory arthritides (IA) cohort.
Methods: Data were obtained from the National Health Insurance Sharing Service database in South Korea, including 161 907 patients with seropositive rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis between 2010 and 2022.
PLoS One
March 2025
Department of Anesthesia, Faculty of Medicine, College of medicine and health science, Hawassa University, Hawassa, Sidama, Ethiopia.
Introduction: Tramadol abuse is a current public health concern in Ethiopia. Drug abuse including that of tramadol is a significant public health issue that causes health, economic, and social problems to individual drug users, their families, the community, and the entire nation. Therefore this study delivers information regarding current tramadol abuse among students of an Ethiopian University.
View Article and Find Full Text PDFPLoS One
March 2025
Department of Pharmacology, Addiction Science and Toxicology, University of Tennessee Health Science Center, Memphis, Tennessee, United States.
Oxycodone abuse frequently begins with prescription oral oxycodone, yet vulnerability factors (e.g. sex, genetics) determining abuse are largely undefined.
View Article and Find Full Text PDFJ Addict Med
March 2025
From the Departments of Family and Community Medicine and Public Health Science, College of Medicine, Pennsylvania State University, Hershey, PA (W-JT); Department of Family and Community Medicine, College of Medicine, Pennsylvania State University, Hershey, PA (KTC, JS); College of Medicine, Pennsylvania State University, Hershey, PA (EJ); and Departments of Family and Community Medicine, Anesthesiology and Perioperative Medicine, and Public Health Science, Pennsylvania State University, Hershey, PA (AEZ).
Objectives: In early 2022, based on limited case-report evidence, the US Food and Drug Administration warned about possible oral health problems associated with transmucosal (sublingual, buccal) buprenorphine formulations commonly used to treat opioid use disorder (OUD). The purpose of this study was to assess the risk of adverse oral health outcomes among adults prescribed transmucosal buprenorphine for OUD.
Methods: This retrospective cohort study utilizing TriNetX claims data consisted of adults diagnosed with OUD in 2002-2019, and who either filled ≥3 transmucosal buprenorphine prescriptions within any 6-month period (buprenorphine cohort) or did not fill any buprenorphine prescriptions (control cohort).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!